Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw

Goodday, Reginald

doi:10.1016/j.coms.2015.06.006

Cited by 24 publications

(18 citation statements)

References 41 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some more severe forms require the use of more invasive surgeries such as mandibulectomy. Finally, in case of infection of the necrotic area, the use of antibiotic is necessary and a regular monitoring will be established …”

Section: Introductionmentioning

confidence: 99%

Denosumab‐related osteonecrosis of the jaw: A retrospective study

Egloff-Juras

Gallois

Salleron

et al. 2017

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Denosumab‐related osteonecrosis of the jaw: A retrospective study

Egloff-Juras

Gallois

Salleron

et al. 2017

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…Before introduction of antiangiogenic treatment, patients should undergo oral screening (including a comprehensive oral exam with radiographs), be informed about maintaining oral hygiene and should receive all necessary dental treatments [151]. The dentist should contact the oncologist before any oral surgery is carried out on patients treated with angiogenesis inhibitors.…”

Section: Recommendations For Oral Surgerymentioning

confidence: 99%

“…The treatment can be reinitiated after mucosal healing. Dental screening and preoperative dental treatments remain key management approaches for prevention of MRONJ and delayed healing [149][150][151].…”

Section: Recommendations For Oral Surgerymentioning

confidence: 99%

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Vigarios

Epstein

Sibaud

2017

Support Care Cancer

143

136

View full text Add to dashboard Cite

Development of biological targeted therapies and immune checkpoint inhibitors has redefined the treatment for many cancers; however, the increasing use of new protocols has led to physicians observing a new spectrum of toxicities. To date, oral adverse events induced by these new anticancer therapies have been mainly reported using nonspecific terminology (Bstomatitis,^Bmucosal inflammation,^Bmucositis^) and remain poorly characterized, with the exception of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis. Oral toxicities of targeted therapies often display very characteristic features which clearly differ from classic oral injuries observed with cytotoxic chemotherapy and/or radiotherapy. In addition, they frequently affect more than 20% of treated patients and can lead to a significant morbidity or permanent treatment discontinuation. Oral mucosal toxicities described in this review include mTOR inhibitor-associated stomatitis (mIAS); stomatitis, benign migratory glossitis, and osteonecrosis of the jaw associated with multi-targeted kinase inhibitors of the VEGF and PDGF receptors; mucositis induced by EGFR inhibitors (in monotherapy or in combination with head and neck radiotherapy and/or chemotherapy); hyperkeratotic lesions with BRAF inhibitors; pigmentary changes and lichenoid reactions secondary to imatinib; and more recent data on the BOsler-Weber-Rendu-like syndrome^described with the antibody-drug conjugate, TDM-1. Finally, we provide, to our knowledge, the first available structured data on oral toxicities induced by the new recently FDA-and EMA-approved monoclonal antibodies targeting PD-1. Clinical management of these targeted therapy-related oral changes is also discussed.

show abstract

“…Periodontal surgical procedures are treated in the same manner as oral and maxillofacial surgical procedures [39]. Evaluation and treatment for MAS-associated endocrinopathies is an essential element of care in FD patients, and should be performed prior to initiating medical or dental treatments.…”

Section: Discussionmentioning

confidence: 99%

Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw

Metwally

Burke

Tsai

et al. 2016

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Purpose Osteonecrosis of the jaw (ONJ) is an established side effect of intravenous bisphosphonates and other anti-resorptive medications. Although bisphosphonates are frequently prescribed for patients with the skeletal disorder fibrous dysplasia (FD), there are no reports of ONJ in this population. This has led some to conclude that FD patients are at low risk for the development of bisphosphonate-related ONJ. Patients and Methods Patients were evaluated as part of a longstanding FD natural history study at the NIH. Results Out of 76 FD patients who were treated with bisphosphonates, four developed ONJ (5.4%). Three patients developed ONJ in areas of FD bone, and one in an area of normal bone. All four patients had features known to be associated with ONJ in the general population, including long-term, high dose, intravenous bisphosphonate treatment, periodontal and endodontic infections, and dentoalveolar surgical procedures. Conclusions These cases establish ONJ as a potential complication of bisphosphonate treatment in patients with FD. The presence of established risk factors for ONJ in this group of FD patients suggests that high risk individuals may be identified prior to the development of ONJ. Clinicians should use caution in prescribing bisphosphonates to FD patients, and should do so only for established indications.

show abstract

Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw

Cited by 24 publications

References 41 publications

Denosumab‐related osteonecrosis of the jaw: A retrospective study

Denosumab‐related osteonecrosis of the jaw: A retrospective study

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw

Contact Info

Product

Resources

About